678 related articles for article (PubMed ID: 31153107)
1. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
Behr J; Nathan SD; Costabel U; Albera C; Wuyts WA; Glassberg MK; Haller H; Alvaro G; Gilberg F; Samara K; Lancaster L
Adv Ther; 2023 Sep; 40(9):3937-3955. PubMed ID: 37391667
[TBL] [Abstract][Full Text] [Related]
3. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
6. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
[TBL] [Abstract][Full Text] [Related]
7. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
9. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.
Albera C; Costabel U; Fagan EA; Glassberg MK; Gorina E; Lancaster L; Lederer DJ; Nathan SD; Spirig D; Swigris JJ
Eur Respir J; 2016 Sep; 48(3):843-51. PubMed ID: 27471208
[TBL] [Abstract][Full Text] [Related]
11. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU
Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
13. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
[TBL] [Abstract][Full Text] [Related]
14. Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.
Wijsenbeek MS; Grutters JC; Wuyts WA
Adv Ther; 2015 Jul; 32(7):691-704. PubMed ID: 26173796
[TBL] [Abstract][Full Text] [Related]
15. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
20. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.
Kreuter M; Bonella F; Maher TM; Costabel U; Spagnolo P; Weycker D; Kirchgaessler KU; Kolb M
Thorax; 2017 Feb; 72(2):148-153. PubMed ID: 27708114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]